Skip to content

Study · Non-randomized trial · n = 13 · 2021

9 results

Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.

Shimatsu A, Nakamura A, Takahashi Y, Fujio S, Satoh F, Tahara S, Nishioka H, Takano K, Yamashita M, Arima H, Tominaga A, Tateishi S, Matsushita Y

Endocrine journal11 Mar 2021Cited by 11 (Europe PMC)

PMID33692246 (opens in a new tab)DOI10.1507/endocrj.ej20-0707 (opens in a new tab)PepBankPUB-33692246
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese TSHoma patients, TSH, FT3, and FT4 decreased during lanreotide treatment, and euthyroid status persisted until final assessment.

    In plain wordsIn Japanese TSHoma patients, thyroid hormone markers decreased during lanreotide treatment, and normal thyroid status persisted until final assessment.

    Peptide
    Lanreotide
    Outcome
    DecreaseThyroid hormone concentrations and euthyroid status
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Source sentences

    Summary
    The serum concentrations of TSH, FT3, and FT4 decreased with treatment, and euthyroid status was maintained until final assessment.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  2. 02HumanNon-randomized trialEfficacy outcome

    At final assessment, FT4 was within reference ranges in 10/13 Japanese TSHoma patients receiving lanreotide.

    In plain wordsAt final assessment, 10/13 Japanese TSHoma patients receiving lanreotide had FT4 within reference ranges.

    Peptide
    Lanreotide
    Outcome
    Not applicableFT4 within reference range
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Measurements

    Patients with FT4 within reference range
    10 patients
    final assessment, of 13 patients

    Source sentences

    Summary
    FT4 at final assessment was within reference ranges in 10/13 patients.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  3. 03HumanNon-randomized trialEfficacy outcome

    In Japanese TSHoma patients receiving lanreotide, median tumor size change was -23.8% (interquartile range -38.1 to -19.8) at final assessment.

    In plain wordsIn Japanese TSHoma patients receiving lanreotide, median pituitary tumor size decreased by 23.8% from baseline.

    Peptide
    Lanreotide
    Outcome
    DecreasePituitary tumor size
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Measurements

    Median percent change in pituitary tumor size from baseline
    −23.8%
    final assessment
    Interquartile range of percent change in pituitary tumor size
    −38.1 to −19.8%
    final assessment

    Source sentences

    Summary
    The median (interquartile range) percent change in pituitary tumor size from baseline at final assessment was -23.8% (-38.1, -19.8).
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  4. 04HumanNon-randomized trialEfficacy outcome

    Clinical symptoms improved during lanreotide treatment in Japanese TSHoma patients.

    In plain wordsClinical symptoms improved during lanreotide treatment in Japanese TSHoma patients.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedClinical symptoms
    Study

    n = 13

    Analysis
    Secondary
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Source sentences

    Summary
    The clinical symptoms were also improved.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  5. 05HumanNon-randomized trialSafety outcome

    Adverse events occurred in 12/13 Japanese TSHoma patients receiving lanreotide.

    In plain wordsAdverse events occurred in 12/13 Japanese TSHoma patients receiving lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableAny adverse event
    Study

    n = 13

    Outcome group
    Adverse events · Whole body
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Measurements

    Patients with adverse events
    12 patients
    of 13 patients

    Source sentences

    Summary
    Regarding safety, adverse events were observed in 12/13 patients, but none discontinued treatment.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  6. 06HumanNon-randomized trialSafety outcome

    No Japanese TSHoma patient discontinued lanreotide treatment.

    In plain wordsNo Japanese TSHoma patient stopped lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    Not applicableTreatment discontinuation
    Study

    n = 13

    Outcome group
    Adverse events · Whole body
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Source sentences

    Summary
    Regarding safety, adverse events were observed in 12/13 patients, but none discontinued treatment.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  7. 07HumanNon-randomized trialSafety outcome

    Gastrointestinal disorders occurred in 12/13 Japanese TSHoma patients receiving lanreotide.

    In plain wordsGastrointestinal disorders occurred in 12/13 Japanese TSHoma patients receiving lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableGastrointestinal disorders
    Study

    n = 13

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Measurements

    Patients with gastrointestinal disorders
    12 patients
    of 13 patients

    Source sentences

    Summary
    The common adverse events were gastrointestinal disorders (12/13 patients) and administration site reactions (5/13 patients).
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  8. 08HumanNon-randomized trialSafety outcome

    Administration site reactions occurred in 5/13 Japanese TSHoma patients receiving lanreotide.

    In plain wordsAdministration site reactions occurred in 5/13 Japanese TSHoma patients receiving lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableAdministration site reactions
    Study

    n = 13

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Measurements

    Patients with administration site reactions
    5 patients
    of 13 patients

    Source sentences

    Summary
    The common adverse events were gastrointestinal disorders (12/13 patients) and administration site reactions (5/13 patients).
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…
  9. 09HumanNon-randomized trialSafety outcome

    No Japanese TSHoma patient receiving preoperative lanreotide developed perioperative thyroid storm.

    In plain wordsNo Japanese TSHoma patient receiving preoperative lanreotide developed a thyroid storm around surgery.

    Peptide
    Lanreotide
    Outcome
    Not applicablePerioperative thyroid storm
    Study

    n = 6

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    90 mg every 4 weeks, adjusted to 60 mg or 120 mgAs given in this study (human).

    Source sentences

    Summary
    The patients receiving preoperative treatment did not develop perioperative thyroid storm.
    1 context sentence
    Summary · context
    A total of 13 Japanese patients with TSHoma were enrolled from February to December 2018 and treated with lanreotide autogel 90 mg every 4 weeks, with dose adjustments to 60 mg or 120 mg. Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from th…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.